Study | Sample type | Analytical platform | Essential amino acid | Non-essential amino acid | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Val | His | Phe | Thr | Leu | Met | Trp | Ile | Lys | Tyr | Gln | Glu | Ser | Asn | Gly | Ala | Arg | Asp | Cys | Pro | |||
GC | ||||||||||||||||||||||
Tugnoli (2006)69 | Tissue | HR-MAS NMR | ↑ | |||||||||||||||||||
Calabrese (2008)68 | Tissue | HR-MAS MRS | ↑ | ↑ | ||||||||||||||||||
Hirayama (2009)66 | Tissue | CE–MS | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||
Wu (2010)61 | Tissue | GC–MS | ↑ | ↑ | ↑ | ↑ | ||||||||||||||||
Yu (2011)58 | Plasma | GC/TOF MS | ↑ | ↑ | ||||||||||||||||||
Song (2012)51 | Serum | GC–MS | ↑ | ↓ | ||||||||||||||||||
Aa (2012)52 | Serum Tissue | GC/TOFMS | ↓ | ↓ | ↓ ↑ | |||||||||||||||||
Jung (2014)39 | Urine Tissue | 1H NMR; HR-MAS NMR | ↑↑ | ↑ | ↑ ↑ | ↑ ↑ | ↑ | ↑ | ↑ | ↑ ↑ | ↑ | ↑ | ↑ ↑ | ↑ | ↑ | |||||||
Chen (2014)41 | Urine | MRB-CE-MS | ↑ | ↓ | ↑ | ↓ | ↑ | ↓ | ↑ | ↓ | ||||||||||||
Yang (2014)43 | Serum | LC–MS | ↑ | ↑ | ||||||||||||||||||
Liang (2015)37 | Urine | LC–MS | ↓ | ↑ | ↑ | |||||||||||||||||
Wang (2016)33 | Tissue | 1H NMR | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | ↑ | |||||||||
Chan (2016)34 | Urine | 1H-NMR | ↑ | |||||||||||||||||||
Kuligowski (2016)35 | Plasma | UPLC–TOFMS | ↓ | ↑ | ||||||||||||||||||
Wang (2017)31 | Serum | HPLCESI/Q-TOFMS | ↑ | ↑ | ↑ | |||||||||||||||||
Lario (2017)25 | Plasma | LC–MS | ↓ | ↓ | ↑ | |||||||||||||||||
Xiu (2018)20 | Plasma | UHPLC–MS/MS | ↑ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↑ | ↓ | ↓ | ↑ | ↓ | ↓ | ||
Jing (2018)23 | Plasma | LC–MS/MS | ↓ | ↓ | ↓ | ↓ | ||||||||||||||||
EC | ||||||||||||||||||||||
Wu (2009)67 | Tissue | GC/MS | ↑ | ↑ | ↑ | ↑ | ↑ | |||||||||||||||
Yakoub (2010)62 | Tissue | NMR | ↑ | |||||||||||||||||||
Ayshamgul (2010)65 | Plasma | 1H NMR | ↓ | ↓ | ↓ | ↓ | ||||||||||||||||
Zhang (2011)60 | Serum | NMR | ↑ | ↑ | ||||||||||||||||||
Zhang (2012)54 | Serum | LC–MS and NMR | ↓ | ↓ | ↓ | ↓ | ↑ | ↓ | ↑ | |||||||||||||
Hasim (2012)53 | Urine Plasma | 1H NMR | ↓ ↓ | ↓ | ↑ | ↓ | ↓ | ↑ | ↑ | ↓ | ||||||||||||
Davis (2012)55 | Urine | 1H NMR | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↑ | |||||||||||||
Ikeda (2012)50 | Serum | GC–MS | ↑ | |||||||||||||||||||
Yang (2013)45 | Tissue | 1H NMR | ↑ | ↑ | ||||||||||||||||||
Zhang (2013)46 | Serum | 1H NMR; UHPLC | ↑ | ↑ | ↑ | ↓ | ↓ | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | |||||||||
Wang (2013)48 | Tissue | 1H NMR | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | ↓ | ↑ | ↓ | ↓ | ||||||||||
Xu (2016)36 | Urine | LC–MS | ↑ | ↑ | ||||||||||||||||||
Zhang (2017)26 | Tissue | LC–MS | ↑ | ↑ | ↓ | ↑ | ↓ | ↑ | ||||||||||||||
Cheng (2017)27 | Serum | UPLC-MS/MS | ↑ | |||||||||||||||||||
Cheng (2017)28 | Serum | LC-MS/MS | ↓ | |||||||||||||||||||
Zhu (2017)29 | Serum Tissue | GC/TOF-MS | ↓ ↑ | ↑ | ↓ ↑ | ↓ ↑ | ↓ ↑ | ↓ ↑ | ↓ ↑ | ↓ ↑ | ↑ ↑ | ↑ | ↑ ↓ | ↓ ↑ | ↓ ↑ | ↓ ↑ | ↓ ↑ | ↓ ↑ | ↑ | ↑ ↑ | ↓ ↑ | |
Reed (2017)30 | Tissue | 1H NMR | ↓ | ↓ | ||||||||||||||||||
Tokunaga (2018)22 | Tissue | CE-TOFMS | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | |
Ma (2018)24 | Serum | 2D LC–MS | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ |
EO, esophageal cancer; GC, gastric cancer; Val, valine; His, histidine; Phe, phenylalanine; Thr, threonine; Leu, leucine; Met, methionine; Trp, tryptophan; Ile, isoleucine; Lys, lysine; Tyr, tyrosine; Gln, glutamine; Glu, glutamic acid; Ser, serine; Asn, asparagine; Gly, glycine; Ala, alanine; Arg, arginine; Asp, aspartic acid; Cys, cystine; Pro, proline; 1H NMR, proton nuclear magnetic resonance; HR-MAS-NMR, high-resolution magic angle spinning-nuclear magnetic resonance spectroscopy; GC–MS, gas chromatography–mass spectrometry; CE–MS, capillary electrophoresis–mass spectrometry; HPLC–MS, high-performance liquid chromatography–mass spectrometry; LC–MS, liquid chromatography–mass spectrometry